| Nov 20 |
Innate Pharma Releases Its 2025 Financial Calendar
|
| Nov 19 |
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
|
| Nov 8 |
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
|
| Nov 7 |
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
|
| Oct 14 |
Innate Pharma appoints Jonathan Dickinson as new CEO and Chairman of executive board
|
| Oct 14 |
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
|
| Oct 14 |
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
|
| Sep 30 |
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
|
| Sep 23 |
Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate
|
| Sep 23 |
FDA grants IND clearance for Innate Pharma’s solid tumour trial
|
